Dr. Siddharth Mathur, MD
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Years since graduation
- 26
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 893
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
FL license ME112492 -
Internal Medicine Physician
NY license 003163
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- HCA Florida Citrus Hospital Inverness, FL
- Tampa General Hospital Crystal River Crystal River, FL
Medical groups
- Bikkasani Ram Hellstern and Chandrupatla MDpa (12 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 893
- Services billed
- 3,737
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Pathology examination of tissue using a microscope, intermediate complexity | 731 | 313 |
| Established patient office or other outpatient visit, 20-29 minutes | 519 | 371 |
| Special stained specimen slides to examine tissue including interpretation and report | 249 | 156 |
| Special stained specimen slides to identify organisms including interpretation and report | 245 | 142 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 219 | 214 |
| Established patient office or other outpatient visit, 30-39 minutes | 194 | 164 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 174 | 109 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 145 | 145 |
| New patient office or other outpatient visit, 30-44 minutes | 140 | 140 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 134 | 133 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Omeprazole Other prescribers in Crystal River, FL | 543 |
| Clenpiq (sod picosulf/mag ox/citric ac) | 387 |
| Pantoprazole Sodium Other prescribers in Crystal River, FL | 112 |
| Gavilyte-C (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Crystal River, FL | 110 |
| Famotidine Other prescribers in Crystal River, FL | 106 |
| Sucralfate Other prescribers in Crystal River, FL | 65 |
| Linzess (linaclotide) Other prescribers in Crystal River, FL | 51 |
| Peg 3350-Electrolyte (sodium chloride/nahco3/kcl/peg) | 44 |
| Metoclopramide Hcl Other prescribers in Crystal River, FL | 42 |
| Colestipol Hcl Other prescribers in Crystal River, FL | 41 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 19 companies reported 98 payments worth $20,048 in total to this clinician.
| Phathom Pharmaceuticals, Inc. | $18,024 |
|---|---|
| Janssen Biotech, Inc. | $558 |
| AbbVie Inc. | $374 |
| Ipsen Biopharmaceuticals, Inc | $296 |
| Intercept Pharmaceuticals, Inc. | $158 |
| Boston Scientific Corporation | $136 |
| Aimmune Therapeutics, Inc. | $89.10 |
| Genzyme Corporation | $74.28 |
| Compensation for services other than consulting (speaking, faculty) | $15,050 |
|---|---|
| Food and Beverage | $2,848 |
| Travel and Lodging | $2,150 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Phathom Pharmaceuticals, Inc. Mar 5, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $2,580 |
| Phathom Pharmaceuticals, Inc. Feb 26, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $2,150 |
| Phathom Pharmaceuticals, Inc. Feb 5, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $2,150 |
| Phathom Pharmaceuticals, Inc. Apr 30, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $2,150 |
| Phathom Pharmaceuticals, Inc. Oct 1, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $2,150 |
| Phathom Pharmaceuticals, Inc. Jan 29, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $2,150 |
| Phathom Pharmaceuticals, Inc. Jan 30, 2025 | Travel and Lodging VOQUEZNA · Gastroenterology · travel to Winter Park, FL | $1,055 |
| Phathom Pharmaceuticals, Inc. Feb 25, 2025 | Travel and Lodging VOQUEZNA · Gastroenterology · travel to Winter Haven, FL | $996 |
| Phathom Pharmaceuticals, Inc. Jan 29, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $860 |
| Phathom Pharmaceuticals, Inc. Feb 5, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $860 |
All 12 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Phathom Pharmaceuticals, Inc. Oct 1, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $2,150 |
| Phathom Pharmaceuticals, Inc. May 27, 2025 | Travel and Lodging VOQUEZNA · Gastroenterology · travel to Ocala, FL | $52.00 |
| Phathom Pharmaceuticals, Inc. Apr 30, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $2,150 |
| Phathom Pharmaceuticals, Inc. Mar 19, 2025 | Travel and Lodging VOQUEZNA · Gastroenterology · travel to Ocala, FL | $46.20 |
| Phathom Pharmaceuticals, Inc. Mar 5, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $2,580 |
| Phathom Pharmaceuticals, Inc. Feb 26, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $2,150 |
| Phathom Pharmaceuticals, Inc. Feb 25, 2025 | Travel and Lodging VOQUEZNA · Gastroenterology · travel to Winter Haven, FL | $996 |
| Phathom Pharmaceuticals, Inc. Feb 5, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $2,150 |
| Phathom Pharmaceuticals, Inc. Feb 5, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $860 |
| Phathom Pharmaceuticals, Inc. Jan 30, 2025 | Travel and Lodging VOQUEZNA · Gastroenterology · travel to Winter Park, FL | $1,055 |
| Phathom Pharmaceuticals, Inc. Jan 29, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $2,150 |
| Phathom Pharmaceuticals, Inc. Jan 29, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $860 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $152,519 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis.
Celgene Corporation - A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis.
E.r. Squibb & Sons, L.l.c. - A Phase 1, open-label, single-sequence study to evaluate potential disease-mediated drug-drug interaction with selected cytochrome P450 substrates in adult subjects with active eosinophilic esophagitis receiving cenda…
Celgene Corporation - EoE-201
Phathom Pharmaceuticals, Inc. - A Multi-Center, Multi-National, Randomized, Double-Blind, Placebo-Controlled Induction and Long-term Controlled Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosino…
Celgene Corporation - A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING)
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.